Targeted Therapies in Oncology
February 2017
Volume: 6
Issue: 2
January 2017
Volume: 6
Issue: 1
November 2016
Volume: 5
Issue: 8
October 2016
Volume: 5
Issue: 7
September 2016
Volume: 5
Issue: 6
July 2016
Volume: 5
Issue: 5
May 2016
Volume: 5
Issue: 4
April 2016
Volume: 5
Issue: 3
March 2016
Volume: 6
Issue: 2
January 2016
Volume: 5
Issue: 1
November 2015
Volume: 4
Issue: 8
October 2015
Volume: 4
Issue: 7
September 2015
Volume: 4
Issue: 6
July 2015
Volume: 4
Issue: 5
May 2015
Volume: 4
Issue: 4
April 2015
Volume: 4
Issue: 2
November 2014
Volume: 3
Issue: 6
September 2014
Volume: 3
Issue: 5
July 2014
Volume: 3
Issue: 4
May 2014
Volume: 3
Issue: 3
March 2014
Volume: 3
Issue: 2
January 2014
Volume: 3
Issue: 1
November 2013
Volume: 2
Issue: 6
September 2013
Volume: 2
Issue: 5
July 2013
Volume: 2
Issue: 4
May 2013
Volume: 2
Issue: 3
March 2013
Volume: 2
Issue: 2
January 2013
Volume: 2
Issue: 1
November 2012
Volume: 1
Issue: 4
September 2012
Volume: 1
Issue: 3
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
5